FDA PCAC July 2026: Panel Backed 6 of 7 Peptides for 503A Compounding

What the July 23-24 hearing actually is

The Pharmacy Compounding Advisory Committee (PCAC) is an FDA advisory body that reviews specific compounds and makes recommendations to FDA about whether those compounds should be placed on (or removed from) the 503A bulk drug substances list. The 503A list determines which substances can legally be compounded by traditional compounding pharmacies for individual patient prescriptions under section 503A of the Federal Food, Drug, and Cosmetic Act.

The committee is composed of pharmacists, physicians, and FDA scientists. It meets periodically to review nominated substances. Compounds undergoing review can be:

• Added to the eligible list, compounding pharmacies can legally prepare them under the standard 503A framework.
• Placed in Category 1, eligible for compounding while certain criteria are met or further data is gathered.
• Placed in Category 2, FDA judgment is that the safety or efficacy package is incomplete for compounded human use; compounding is not generally permitted. This is BPC-157's current status from 2023.
• Explicitly denied / removed, compounding is prohibited.
• Returned for further data, committee defers a decision pending additional information.

The July 23-24, 2026 meeting reviewed seven peptides simultaneously, an unusually broad agenda for a single PCAC meeting and a clear signal that FDA is consolidating review of the peptide-compounding space. The outcomes will substantially reshape compounding-pharmacy access for some of the most-discussed compounds in modern peptide medicine.

Two clarifications are worth making up front. First, being eligible to compound under 503A is not the same as FDA drug approval: a compound can be added to the Bulks List and still not be an FDA-approved drug, and none of these seven are approved drugs. Second, PCAC only recommends; FDA makes the final determination, published later through the Federal Register under docket FDA-2025-N-6895. A recommendation is a strong signal, not a rule.

The seven peptides under review

The agenda splits the seven across two days. July 23 covers BPC-157, KPV, TB-500, and MOTS-c; July 24 covers Emideltide (DSIP), Semax, and Epitalon. For each, FDA evaluated a specific proposed use and assessed the evidence against it:

• BPC-157 — ulcerative colitis.
• KPV — wound healing and inflammatory conditions.
• TB-500 — wound healing.
• MOTS-c — obesity and osteoporosis.
• Emideltide (DSIP) — opioid withdrawal, chronic insomnia, and narcolepsy.
• Semax — cerebral ischemia, migraine, and trigeminal neuralgia.
• Epitalon — insomnia.

1. BPC-157

Current status: Category 2 since 2023 (incomplete safety package for compounded human use).

What's at stake: Whether BPC-157 moves out of Category 2 toward broader compounding eligibility, or remains restricted. Given the substantial community use, the size of the research literature (overwhelmingly preclinical rodent work), and the FDA's stated concerns about incomplete human safety characterization, the outcome is uncertain. A move toward eligibility would substantially expand compounding-pharmacy access; staying in Category 2 maintains the current grey-market-dominant access pattern.

Evidence package the FDA will weigh: Decades of rodent injury-model literature from the Sikiric group and others; minimal completed human RCT evidence; substantial community use without formal harm signals; ongoing concerns about theoretical angiogenic / cancer-promotion considerations. See our BPC-157 page for the full evidence framework.

2. TB-500 (Thymosin Beta-4 fragment)

Current status: Category 2 (similar regulatory framework to BPC-157).

What's at stake: Whether the synthetic TB-500 fragment can move toward compounding eligibility. The 17-aa active fragment is structurally distinct from full-length thymosin beta-4, which has more clinical evidence; the FDA may treat them differently. Important nuance: the full-length thymosin beta-4 has undergone clinical development; TB-500 the marketed fragment has thinner direct human evidence.

Evidence package: Preclinical actin-binding and wound-healing biology; some human evidence for full-length TB-4 in ocular and cardiac contexts; thinner direct evidence for the TB-500 fragment specifically. See our TB-500 page.

3. KPV

Current status: Category 2 / under review.

What's at stake: KPV's human evidence is thinner than community discussion implies. The most-cited clinical data comes from a KPV-based candidate (Lipotropin-1/Zengen) in ulcerative colitis rather than KPV itself, and FDA's reviewers concluded that evidence in clinical patient populations is limited, with most support coming from laboratory and mouse-model work. A move toward compounding eligibility would expand IBD and gut-mucosal-disease access; staying restricted maintains the grey-market access pattern. The KPV review may be among the more favorable cases given the clinical-grade IBD evidence base, but the FDA's overall stance toward small-peptide compounding is the dominant variable.

Evidence package: Small clinical work on a KPV-based candidate in ulcerative colitis, a well-characterized NF-κB inhibition mechanism, established α-MSH C-terminal fragment biology, and substantial rodent colitis data, against which FDA judged the human record insufficient. See our KPV page.

4. MOTS-c

Current status: Investigational; compounding eligibility under review.

What's at stake: MOTS-c is a mitochondrial-derived peptide with substantial observational human evidence (declining levels with age, exercise-induced increases) but limited exogenous administration trial data. The FDA may view this as too early in clinical development for compounding eligibility. A favorable decision would expand longevity-medicine access; an unfavorable decision keeps MOTS-c primarily in the research-peptide channel.

Evidence package: Observational human studies, foundational mechanism papers (Lee et al. 2015 Cell Metab, Reynolds et al. 2021 Nat Commun), thinner exogenous administration evidence. See our MOTS-c page.

5. Semax

Current status: Compounding access varies by state; under review for federal 503A clarification.

What's at stake: Semax is a prescription nootropic in Russia with substantial Russian-language clinical evidence in cognitive impairment contexts. The Western evidence base is thinner. FDA decision will substantially affect the cognitive-peptide compounding market and may set a precedent for how the agency handles compounds with substantial non-Western clinical evidence.

Evidence package: Substantial Russian clinical evidence, mechanism characterization in ACTH-fragment biology, thinner Western RCT validation. See our Semax page.

6. Epitalon

Current status: Compounding access varies by state; under review.

What's at stake: Epitalon is the most-discussed Khavinson peptide internationally and has substantial community interest in longevity contexts. The evidence base is dominated by the originating Khavinson research lineage; independent Western validation is limited. FDA decision will affect both individual-Epitalon access and may signal the agency's stance toward the broader Khavinson bioregulator family.

Evidence package: Khavinson-lineage clinical observations, telomerase-activation hypothesis, thinner independent replication. See our Epitalon page.

7. DSIP (Delta Sleep-Inducing Peptide)

Current status: Limited compounding access; under review.

What's at stake: DSIP has been in research peptide channels for decades with substantial community interest in sleep and stress contexts. Formal clinical evidence is thin. FDA decision will affect sleep-peptide compounding broadly.

Evidence package: Historical research and small clinical studies primarily from European groups; mechanism not fully characterized; community use substantial. See our DSIP page.

What the committee actually decided

Going into the meeting the base case was that PCAC would follow its staff reviewers and decline most or all seven. It did the opposite on six of them.

• BPC-157, KPV, TB-500 — recommended, 8-6 with one abstention each.
• MOTS-c — recommended, 7-5 with two abstentions.
• Semax — recommended, 8-5 with one abstention.
• Epitalon — recommended, 7-5 with one abstention.
• Emideltide (DSIP) — not recommended, 6-7 with one abstention.

The composition of the panel is the part worth understanding. Eight temporary members had been added to the committee before the meeting, and their votes supplied the winning margins on every compound that passed. That is why the outcome diverged so sharply from the staff review: the scientific record FDA summarized did not change between the briefing documents and the vote — the group weighing it did.

The Kennedy HHS has taken a notably permissive stance on compounding access, including the February 2026 reclassification that restored Thymosin Alpha-1 eligibility. The July votes are consistent with that direction. Readers should hold both facts at once: the committee has recommended these six, and FDA's career reviewers concluded the evidence did not support them.

What this means for current users

If you currently access these peptides through a compounding pharmacy

The recommendation matters for your access pattern eventually, but not yet. Nothing changed legally on July 24. For any of the six to become compoundable under 503A, FDA must publish a proposed rule, take public comment, and issue a final rule — a sequence that realistically extends into 2027 and beyond, and that FDA is not obliged to complete in the committee's favor.

• If eligibility expands: Compounding access may become more available, more states may permit it, and pricing competition may improve.
• If eligibility tightens or remains restricted: Your compounding pharmacy may need to stop production or transition you to alternatives. Plan for potential supply disruption.

If you currently access these peptides through research-peptide channels

The PCAC decision doesn't directly govern grey-market research-peptide supply, but the regulatory signal still matters:

• A favorable PCAC decision opens an alternative legitimate-supply pathway through compounding pharmacies, generally a better access route than research-peptide vendors for clinical use cases.
• An unfavorable PCAC decision may accelerate DOJ and FDA enforcement attention on the broader research-peptide market, see our State of the Peptide Market 2026 article for the March 2026 enforcement context.
• For peptides where compounding becomes available, transitioning from research-peptide channels to a compounding pharmacy under qualified-prescriber supervision is typically the more defensible long-term access pathway.

What to be doing right now

• Track the July 23-24 hearing through FDA public communications and federal register announcements.
• If you're on any of these seven peptides through a compounding pharmacy, talk to your prescriber about contingency planning before the meeting.
• For broader access strategy, read our State of the Peptide Market 2026 piece for the broader regulatory environment, and our are peptides safe pillar for the per-compound risk framework.

The practical read

The July 23-24, 2026 PCAC hearing is the most consequential peptide-compounding regulatory event of 2026, seven of the most-discussed peptides in modern medicine reviewed in a single meeting. The outcome will substantially shape compounding-pharmacy access for these compounds and signal the FDA's broader stance toward peptide compounding under the current HHS framework.

Realistic expectations should be calibrated: with FDA staff recommending against all seven, the base case is that the committee declines most or all rather than delivering a mixed or favorable result. The compounds with the strongest formal human evidence (KPV's IBD Phase 2 signal, MOTS-c's mechanism characterization) have the strongest cases; the compounds with primarily preclinical or non-Western evidence bases have weaker cases. BPC-157's current Category 2 status from 2023 makes a substantial favorable shift less likely than for compounds without that prior negative determination.

For users currently relying on these peptides, the practical recommendation is to track the outcome closely, plan for potential access disruption on compounds that may lose or fail to gain eligibility, and consider whether the broader regulatory signal indicates it's time to transition to clinician-supervised access pathways for compounds where eligibility opens up. For the broader regulatory landscape see our coverage of the 2026 peptide market, and for compound-specific risk and access frameworks see the per-peptide pages.